Revance Therapeutics (RVNC) Reports Q2 Loss of $0.90/Share

Revance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($0.90), versus ($0.88) reported last year.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
• Raymond James Previews Charles Schwab Corp. (SCHW) Earnings: 'Elevated Trading Volumes Drives Trading Revenue Upside'
• WD-40 Co. (WDFC) Tops Q3 EPS by 76c; offers guidance